🇺🇸 FDA
Patent

US 8501695

Tissue kallikrein for the treatment of diseases associated with amyloid protein

granted A61KA61K31/14A61K31/407

Quick answer

US patent 8501695 (Tissue kallikrein for the treatment of diseases associated with amyloid protein) held by DiaMedica Inc. expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
DiaMedica Inc.
Grant date
Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/14, A61K31/407, A61K31/685, A61K36/16